FDA's Plausible Mechanism Pathway For Personalized Gene Therapies

By Liz Spehalski, Ph.D., Principal Consultant, Regulatory Consulting; Steve Winitsky, M.D., Senior Vice President, Technical, Regulatory Consulting

Personalized gene therapies are redefining what medicine can deliver—one patient at a time. Yet these individualized treatments often challenge traditional regulatory frameworks built for standardized products. As innovation accelerates, the FDA is introducing new approaches to ensure breakthrough therapies reach patients without unnecessary delay.

One such approach is the Agency’s emerging “plausible mechanism” pathway, designed to support faster evaluation of personalized gene therapies when traditional evidentiary requirements may not align with ultra‑small patient populations. This article examines the scientific and regulatory rationale behind this pathway and how it could reshape approval strategies for bespoke genetic interventions. Key considerations include evidentiary flexibility, the role of mechanistic understanding, and how regulators assess benefit–risk in highly individualized contexts.

Sponsors developing personalized therapies must adapt their development and regulatory planning accordingly. By understanding this evolving pathway early, teams can position programs for accelerated review and maximize the impact of next‑generation precision treatments.